The Difference Between Necitumumab and Cetuximab

Necitumumab and cetuximab ( Cetuxiab) are two different monoclonal antibody drugs with differences in structure, indications, mechanism of action and adverse reactions. The specific drug to use needs to be determined based on the patient's condition, the doctor's advice, and the drug's approved indications.

1. Structure: Nexituzumab is made from a humanized antibody that binds to the outer domain of the epidermal growth factor receptor (EGFR). Cetuximab is also a humanized antibody, but it can bind to both the outer domain and the intramembrane structure of EGFR.

2. Indications: Nexituzumab is mainly used for the treatment of advanced non-small cell lung cancer, and is often used in combination with chemotherapy drugs. Cetuximab is widely used in the treatment of various cancers, including colorectal cancer, head and neck cancer, etc.

3. Mechanism of action: Nexituzumab inhibits tumor growth and spread by binding EGFR and blocking its signaling pathway. Cetuximab has a similar mechanism of action, but it can also induce apoptosis and immune responses through other mechanisms.

4. Adverse reactions: The two drugs also differ in terms of adverse reactions. Nexituzumab may cause drug-related rash, thromboembolism and other adverse reactions. Cetuximab may cause allergic reactions, rash, nausea, vomiting, etc.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.